Company intelligence / Profile preview

Ahno

Ownership: Private
Development stage: Other

Overview

AnHorn Medicines has advanced its lead candidate, AH-001, a first-in-class protein degrader targeting androgen receptor for androgenetic alopecia, into Phase 1 clinical trials in the United States. Preclinical studies showed reversal of DHT-induced hair loss and promotion of hair follicle regrowth. The company leverages an AI-driven platform to accelerate drug discovery focused on targeted protein degradation.

Therapeutic areas: Dermatology
Modalities: Small moleculeMolecular glue therapyBi-functional ligand induced proteolysis (protein degrader)
Industry: Biotech

Beyond the preview

Go deeper on Ahno.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ahno.

Explore the full profile